Clinical Study of Recombinant Anti-HER2 Humanized Monoclonal Antibody (GB221) for Injection

Clinical trial NCT04164615 · UNKNOWN

Trial details

NCT number: NCT04164615
Sponsor: Genor Biopharma Co., Ltd.
Status: UNKNOWN
Phase: Phase 3
Study type: INTERVENTIONAL

HER-2-positive Advanced Breast Cancer

Start date: 2016-11-24
Primary completion: 2020-07-01
Enrollment: 336

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.